Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Inlyta (axitinib by Year
Inlyta (axitinib — renal cell carcinoma) — U.S. revenues ($M) ($M)
Pfizer Inlyta (axitinib: $516M in FY2025, down 12.2% from a year earlier.
Latest, FY2025
516
Period ended Dec 31, 2025
Change on a year earlier
-12.2%
588 in FY2024
History
10 years
Since FY2016
Sources
9
Documents cited below
Where the FY2025 figure comes from
“|| Inlyta | 923 | 978 | (6%) | (6%) | 516 | 588 | (12%) | 407 | 391 | 4% | 4%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up inlyta (axitinib
Cite this data
StockData. (2026). Pfizer Inlyta (axitinib ($M), annual FY2016–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/inlyta-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.